(Q44605407)

reason for preferred rank

4 December 2017

title

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001 (English)

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

17 March 2024

Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523276

17 March 2024

0 references

1 reference

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

17 March 2024

6

Kiat Ruxrungtham

1 reference

4 December 2017

8

Praphan Phanuphak

1 reference

4 December 2017

2

Gregory J Dore

1 reference

4 December 2017

1

W. Phillip Law

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523276

17 March 2024

5

Mark A. Boyd

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523276

17 March 2024

author name string

Apicha Mahanontharit

4

1 reference

4 December 2017

Chris J. Duncombe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523276

17 March 2024

Joep M. A. Lange

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523276

17 March 2024

David A. Cooper

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523276

17 March 2024

language of work or name

English

0 references

publication date

1 October 2003

1 reference

4 December 2017

17 October 2003

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14523276

full work available at URL

17 March 2024

https://pdfs.journals.lww.com/aidsonline/2003/10170/Risk_of_severe_hepatotoxicity_associated_with.7.pdf?token=method|ExpireAbsolute;source|Journals;ttl|1544117137975;payload|mY8D3u1TCCsNvP5E421JYK6N6XICDamxByyYpaNzk7FKjTaa1Yz22MivkHZqjGP4kdS2v0J76WGAnHACH69s21Csk0OpQi3YbjEMdSoz2UhVybFqQxA7lKwSUlA502zQZr96TQRwhVlocEp/sJ586aVbcBFlltKNKo+tbuMfL73hiPqJliudqs17cHeLcLbV/CqjlP3IO0jGHlHQtJWcICDdAyGJMnpi6RlbEJaRheGeh5z5uvqz3FLHgPKVXJzdN2ziiHhY6wPF9tfA80junhzNsvd7cOtsWAegtWHHoVA=;hash|4Y6J+4CjyVn5ZnGARZB8DA==

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14523276

http://journals.lww.com/00002030-200310170-00007

17 March 2024

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

17 March 2024

1 reference

4 December 2017

volume

17

1 reference

4 December 2017

issue

15

1 reference

4 December 2017

page(s)

2191-2199

1 reference

AIDS 2001. Clinical treatment. Overview

4 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Hepatotoxicity after introduction of highly active antiretroviral therapy

17 March 2024

2

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

17 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

17 March 2024

4

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

17 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

17 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

17 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

17 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Bridging the divide: global inequities in access to HIV/AIDS therapy

17 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Morbidity and Mortality Weekly Report

17 March 2024

10

41

1

1992

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Hepatitis C virus infection

17 March 2024

11

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Discontinuation rates for protease inhibitor regimens containing ritonavir 600 mg versus ritonavir 400 mg plus saquinavir 400 mg.

17 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests

17 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

17 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

Factors Associated with Mortality in Human Immunodeficiency Virus Type 1–Infected Adults Initiating Protease Inhibitor–Containing Therapy: Role of Education Level and of Early Transaminase Level Elevation (APROCO–ANRS EP11 Study)

17 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/00002030-200310170-00007

17 March 2024

Identifiers

1 reference

4 December 2017

1 reference